To inhibit erlotinib-induced VEGF formation in HCC cells, we have applied N-acetylcysteine, which is commonly used in the therapy of acute liver failure [52, 53] and reduces liver damage in experimental hepatic fibrosis [54]. Here, VEGFA is linked to Hepatic fibrosis.